Amarantus Bioscience Holdings Inc
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprieta… Read more
Market Cap & Net Worth: Amarantus Bioscience Holdings Inc (AMBS)
Amarantus Bioscience Holdings Inc (PINK:AMBS) has a market capitalization of $315.20K ($315.20K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #50890 globally and #15616 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amarantus Bioscience Holdings Inc's stock price $0.00 by its total outstanding shares 630407411 (630.41 Million).
Amarantus Bioscience Holdings Inc Market Cap History: 2015 to 2025
Amarantus Bioscience Holdings Inc's market capitalization history from 2015 to 2025. Data shows change from $400.31 Million to $315.20K (-55.43% CAGR).
Amarantus Bioscience Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amarantus Bioscience Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.24x
Amarantus Bioscience Holdings Inc's market cap is 11.24 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $8.26 Million | $20.00 Million | $18.38 Million | 0.41x | 0.45x |
| 2020 | $5.04 Million | $74.70K | -$628.00K | 67.51x | N/A |
| 2022 | $1.07 Million | $95.33K | -$4.76 Million | 11.24x | N/A |
Competitor Companies of AMBS by Market Capitalization
Companies near Amarantus Bioscience Holdings Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Amarantus Bioscience Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Amarantus Bioscience Holdings Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Amarantus Bioscience Holdings Inc's market cap moved from $400.31 Million to $ 315.20K, with a yearly change of -55.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $315.20K | +400.00% |
| 2024 | $63.04K | -80.00% |
| 2023 | $315.20K | -70.59% |
| 2022 | $1.07 Million | -89.63% |
| 2021 | $10.34 Million | +105.00% |
| 2020 | $5.04 Million | -38.93% |
| 2019 | $8.26 Million | -34.50% |
| 2018 | $12.61 Million | -85.82% |
| 2017 | $88.89 Million | +426.12% |
| 2016 | $16.89 Million | -95.78% |
| 2015 | $400.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Amarantus Bioscience Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $315.20K USD |
| MoneyControl | $315.20K USD |
| MarketWatch | $315.20K USD |
| marketcap.company | $315.20K USD |
| Reuters | $315.20K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.